NASDAQ:PLXSPlexus Stock Price, Forecast & News

Plexus' stock was trading at $60.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PLXS shares have increased by 29.3% and is now trading at $78.47.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Plexus in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Plexus.

Plexus is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Plexus.

Plexus Corp. (NASDAQ:PLXS) released its quarterly earnings data on Wednesday, July, 22nd. The technology company reported $1.20 EPS for the quarter, beating the Zacks' consensus estimate of $0.75 by $0.45. The technology company had revenue of $857.39 million for the quarter, compared to analysts' expectations of $801.94 million. Plexus had a net margin of 3.55% and a return on equity of 12.41%.
View Plexus' earnings history.

Plexus updated its fourth quarter earnings guidance on Wednesday, July, 22nd. The company provided EPS guidance of $1.05 to $1.20 for the period, compared to the Thomson Reuters consensus estimate of $0.90. The company issued revenue guidance of $850 million to $890 million, compared to the consensus revenue estimate of $820.47 million.

6 brokers have issued 1 year target prices for Plexus' stock. Their forecasts range from $72.00 to $91.00. On average, they anticipate Plexus' stock price to reach $81.60 in the next year. This suggests a possible upside of 4.0% from the stock's current price.
View analysts' price targets for Plexus.

Media stories about PLXS stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Plexus earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned press coverage about the technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Plexus.

Plexus saw a decrease in short interest during the month of July. As of July 31st, there was short interest totaling 772,800 shares, a decrease of 21.3% from the July 15th total of 981,700 shares. Based on an average daily trading volume, of 226,800 shares, the short-interest ratio is currently 3.4 days. Approximately 2.7% of the shares of the company are sold short.
View Plexus' Short Interest.

Some companies that are related to Plexus include Trimble (TRMB), IPG Photonics (IPGP), Jabil (JBL), Mercury Systems (MRCY), Fabrinet (FN), Sanmina (SANM), TTM Technologies (TTMI), Methode Electronics (MEI), Benchmark Electronics (BHE), CTS (CTS), Park Electrochemical (PKE), Key Tronic (KTCC) and Neonode (NEON).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Plexus investors own include Bristol-Myers Squibb (BMY), Walgreens Boots Alliance (WBA), Berry Global Group (BERY), Cisco Systems (CSCO), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), QUALCOMM (QCOM), Twitter (TWTR) and ConocoPhillips (COP).

Plexus trades on the NASDAQ under the ticker symbol "PLXS."

Plexus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (3.66%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.41%), Fisher Asset Management LLC (1.97%), Chartwell Investment Partners LLC (1.00%), New York State Common Retirement Fund (0.85%) and Principal Financial Group Inc. (0.77%). Company insiders that own Plexus stock include Angelo Michael Ninivaggi Jr, David J Drury, Dean A Foate, Michael V Schrock, Patrick John Jermain, Peter Kelly, Ralf R Boer, Ronnie Darroch, Scott Theune, Stephen P Cortinovis, Steven J Frisch, Todd P Kelsey and Yong Jin Lim.
View institutional ownership trends for Plexus.

PLXS stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, First Trust Advisors LP, SG Americas Securities LLC, Fisher Asset Management LLC, State Board of Administration of Florida Retirement System, Principal Financial Group Inc., Vident Investment Advisory LLC, and Vident Investment Advisory LLC. Company insiders that have sold Plexus company stock in the last year include Angelo Michael Ninivaggi Jr, David J Drury, Dean A Foate, Michael V Schrock, Patrick John Jermain, Ronnie Darroch, Scott Theune, Stephen P Cortinovis, Steven J Frisch, Todd P Kelsey, and Yong Jin Lim.
View insider buying and selling activity for Plexus.

PLXS stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., New York State Common Retirement Fund, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Assenagon Asset Management S.A., Meritage Portfolio Management, Mackay Shields LLC, Chartwell Investment Partners LLC, and Strs Ohio.
View insider buying and selling activity for Plexus.

Shares of PLXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PLXS stock can currently be purchased for approximately $78.47.

Plexus has a market capitalization of $2.29 billion and generates $3.16 billion in revenue each year. The technology company earns $108.62 million in net income (profit) each year or $3.43 on an earnings per share basis. Plexus employs 19,000 workers across the globe.

The official website for Plexus is www.plexus.com.

Plexus' mailing address is One Plexus Way, Neenah WI, 54957. The technology company can be reached via phone at 920-969-6000 or via email at [email protected]